here is a growing need for new treatments of neurological and psychiatric diseases. Drug development is increasingly difficult and more expensive. Promising new experimental treatments often fail during clinical trials. This is often partly due to a poor transition from preclinical to clinical drug research. My work is devoted to the improvement of this process. Drug development is complex and multidisciplinary, and education of preclinical and clinical graduate and PhD students is essential. New models of drug effects and diseases are designed to improve predictions of desired and undesired effects of novel agents. At CHDR, these developments are brought into practice, with drug studies and consultancy projects in close conjunction with the pharmaceutical industry and the university.

The title of his inaugural lecture was 'Het benevelde brein: de Delyside-challenge-test van Sandoz'

Publications